Editorial Material
Virology
Syeda Kanza Kazmi, Fatima Muhammad Asad Khan, Valentino Natoli, Reem Hunain, Zarmina Islam, Ana Carla dos Santos Costa, Shoaib Ahmad, Mohammad Yasir Essar
Summary: Hepatitis is a significant cause of mortality worldwide, with around 1.34 million deaths annually. Africa is not immune to this issue, with an estimated 100 million individuals infected with Hepatitis B or C. The continent, already fragile, is further burdened by the onset of the COVID-19 pandemic, which could potentially worsen the threat from viral diseases like Hepatitis. Strengthening prevention policies is essential for Africa to build resilience against such threats.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Public, Environmental & Occupational Health
Samina Ejaz, Iqra Abdullah, Waqas Nazir Malik, Shazia Anjum, Muhammad Ashraf, Naveed Akhtar, Aurangzeb Khan, Yasir Hameed, Muhammad Usman, Usman Cheema, Safeena Sidiq
Summary: This study aims to investigate the prevalence and associated risk factors of hepatitis among students and employees in Pakistan and implement measures to make IUB hepatitis free. The study found that hepatitis is more prevalent in men and is associated with sharing of needles and certain behavioral and medical factors.
FRONTIERS IN PUBLIC HEALTH
(2023)
Review
Gastroenterology & Hepatology
Hye Won Lee, Hankil Lee, Beom Kyung Kim, Young Chang, Jae Young Jang, Do Young Kim
Summary: Hepatitis C virus (HCV) infection is the second leading cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and the incidence increases with age. The underdiagnosis of HCV is a major barrier to elimination, and universal screening for HCV in adults has been suggested to improve detection. Recent studies have shown that universal screening and treatment using direct-acting antivirals are cost-effective approaches for prevention and treatment of HCV infection.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Review
Public, Environmental & Occupational Health
Juliette Laure Ndzie Ondigui, Sebastien Kenmoe, Cyprien Kengne-Nde, Jean Thierry Ebogo-Belobo, Guy Roussel Takuissu, Raoul Kenfack-Momo, Donatien Serge Mbaga, Serges Tchatchouang, Josiane Kenfack-Zanguim, Robertine Lontuo Fogang, Elisabeth Zeuko'o Menkem, Ginette Irma Kame-Ngasse, Jeannette Nina Magoudjou-Pekam, Arnol Bowo-Ngandji, Nadege Mafopa Goumkwa, Seraphine Nkie Esemu, Lucy Ndip, Sara Honorine Riwom Essama, Judith Torimiro
Summary: This study assessed the overall prevalence of occult hepatitis B and C infections in Africa and found a high prevalence with variations between countries and population groups.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)
Review
Obstetrics & Gynecology
Jodie Dionne-Odom, Gabriella D. Cozzi, Ricardo A. Franco, Basile Njei, Alan T. N. Tita
Summary: Viral hepatitis in pregnancy can be caused by various viruses, and it is important to have a high clinical suspicion and awareness of risk factors for infection. The route of infection varies depending on the virus. Serologic and molecular testing are helpful for diagnosis of viral hepatitis.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Summary: The clinical efficacy of lenvatinib was compared between hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and hepatitis C virus (HCV)-related HCC. The study found that patients with HBV-HCC had higher objective response rate and disease control rate compared to HCV-HCC, but there were no significant differences in progression-free survival and overall survival between the two groups. Multivariate regression analysis identified HBV infection and antiviral time > 5 years as independent favorable factors for progression-free survival. Overall, lenvatinib seemed to be more effective in HBV-related HCC compared to HCV-related HCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biophysics
Ru Cheng, Fu Zhu, Min Huang, Qiang Zhang, Hui Hong Yan, Xiao Hui Zhao, Fu Kang Luo, Chun Mei Li, Hui Liu, Gao Lin Liang, Cheng Zhi Huang, Jian Wang
Summary: In this study, a new biosensor named hepatitis virus indicator was developed for the simultaneous detection of HBV and HCV. The biosensor utilized Exo III assisted signal amplification strategy and particle counting technology with a dark-field microscopy, enabling sensitive and selective detection.
BIOSENSORS & BIOELECTRONICS
(2022)
Review
Public, Environmental & Occupational Health
Chrissy P. B. Moonen, Casper D. J. den Heijer, Nicole H. T. M. Dukers-Muijrers, Ragni van Dreumel, Sabine C. J. Steins, Christian J. P. A. Hoebe
Summary: This systematic review identified the barriers and facilitators for hepatitis B and C screening among migrants in the European Union/European Economic Area (EU/EEA). The major barriers were related to the migrant and community level, such as knowledge, awareness, culture, religion, and support. The organizational and economic level, including capacity, resources, and coordinated structures, also played a significant role.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Public, Environmental & Occupational Health
Houssein H. Ayoub, Sarwat Mahmud, Hiam Chemaitelly, Laith J. Abu-Raddad
Summary: This study investigated the impact of direct-acting antivirals (DAAs) as hepatitis C virus (HCV) treatment as prevention (HCV-TasP) in MENA region. The results showed that HCV-TasP is an effective intervention to control HCV epidemic in MENA and achieve elimination by 2030.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Immunology
Nicole E. Skinner, Clinton O. Ogega, Nicole Frumento, Kaitlyn E. Clark, Srinivasan Yegnasubramanian, Kornel Schuebel, Jennifer Meyers, Anuj Gupta, Sarah Wheelan, Andrea L. Cox, James E. Crowe Jr, Stuart C. Ray, Justin R. Bailey
Summary: By analyzing the B cell receptors (BCRs) of HCV-infected individuals, researchers identified distinctive BCR features associated with broad neutralization of HCV. These features include long heavy chain complementarity determining region 3 (CDRH3) regions, specific VH gene usage, increased frequencies of somatic hypermutation, and particular VH gene mutations. Further study of these antibodies can inform HCV vaccine development.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Virology
Mengqi Luo, Lingyan Zhang, Chou Yang, Bin Zhou, Jinlin Hou, De-Ke Jiang
Summary: This study found that single-nucleotide polymorphism CXCL13_rs76084459 is significantly associated with response to PegIFNa therapy in patients with chronic hepatitis B. Furthermore, a polygenic score composed of 6 SNPs including CXCL13_rs76084459 has a better predictive value for PegIFNa treatment response.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Review
Gastroenterology & Hepatology
Wenjing Zhang, Fan Du, Li Wang, Tao Bai, Xiang Zhou, Heng Mei
Summary: Epidemiological studies have found a connection between hepatitis C virus (HCV) and hepatitis B virus (HBV) infection and non-Hodgkin lymphoma (NHL) over the past decade. The regression of HCV-associated NHL after HCV eradication provides strong evidence for the role of HCV infection in lymphoproliferative diseases. HBV infection has been shown to significantly increase the incidence of NHL. The exact mechanisms of HCV and HBV leading to NHL are still not fully understood, but they involve the effects of viral presence on B lymphocytes.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Article
Biophysics
Suchanat Boonkaew, Abdulhadee Yakoh, Nattaya Chuaypen, Pisit Tangkijvanich, Sirirat Rengpipat, Weena Siangproh, Orawon Chailapakul
Summary: Electrochemical paper-based analytical devices (ePADs) are simple, portable, and low-cost analytical devices for point-of-care testing of clinical biomarkers. A sequential ePAD has been developed for simultaneous detection of hepatitis B surface antigen and hepatitis C core antigen by integrating dual flow behaviors, avoiding the need for complex multi-step reagent manipulation by the user. The proposed ePAD shows high promise as an easy-to-use, portable, and extendable sensor for other multiplex biological assays.
BIOSENSORS & BIOELECTRONICS
(2021)
Article
Biochemistry & Molecular Biology
Yaojia Ma, Shingo Nakamoto, Junjie Ao, Na Qiang, Tadayoshi Kogure, Keita Ogawa, Miyuki Nakagawa, Kisako Fujiwara, Terunao Iwanaga, Ryuta Kojima, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Naoya Kanogawa, Soichiro Kiyono, Masato Nakamura, Takayuki Kondo, Ryo Nakagawa, Sadahisa Ogasawara, Ryosuke Muroyama, Tetsuhiro Chiba, Jun Kato, Naoya Kato
Summary: In this study, antiviral compounds targeting HBx protein were identified by analyzing HBx binding activity. Tranilast, one of the identified compounds, was found to inhibit HBV replication and infection without affecting cell viability. These findings provide new insights into the development of drugs for the treatment of HBV infection.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Erkin Musabaev, Chris Estes, Shakhlo Sadirova, Shokhista Bakieva, Krestina Brigida, Rick Dunn, Shyamasundaran Kottilil, Poonam Mathur, Ameer Abutaleb, Kathryn Razavi-Shearer, Tim Anstiss, Bakhodir Yusupaliev, Homie Razavi
Summary: Chronic infection with HBV and HCV is a major cause of liver disease and mortality in Uzbekistan. This study demonstrated the feasibility of large-scale simplified testing and treatment to implement a national viral hepatitis elimination program.
LIVER INTERNATIONAL
(2023)
Letter
Gastroenterology & Hepatology
Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jerome Boursier, Philippe Mathurin, Celine Ribet, Victor de Ledinghen, Marie Zins, Marie-Aline Charles
Letter
Biophysics
Armelle Otiniano, Zoe van de Wyngaert, Eolia Brissot, Remy Dulery, Joel Gozlan, Anne Daguenel, Yasmine Abi Aad, Laure Ricard, Nicolas Stocker, Anne Banet, Agnes Bonnin, Tamim Alsuliman, Zora Marjanovic, Aurelie Schnuriger, Paul Coppo, Ollivier Legrand, Karine Lacombe, Mohamad Mohty, Florent Malard
BONE MARROW TRANSPLANTATION
(2023)
Article
Infectious Diseases
Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulie, Sofia Kaisaridi, Clovis Lusivika-Nzinga, Karen Zafilaza, Celine Dorival, Laura Nailler, Anais Boston, Anne-Marie Ronchetti, Clea Melenotte, Andre Cabie, Christophe Choquet, Albert Trinh-Duc, Karine Lacombe, Geraldine Gaube, Francois Coustilleres, Valerie Pourcher, Jean-Philippe Martellosio, Nathan Peiffer-Smadja, Marie Chauveau, Pierre Housset, Lionel Piroth, Mathilde Devaux, Gilles Pialoux, Aurelie Martin, Vincent Dubee, Jerome Frey, Audrey Le Bot, Charles Cazanave, Philippe Petua, Roland Liblau, Fabrice Carrat, Youri Yordanov
Summary: This study compared the clinical and virological outcomes in Omicron BA.1 and BA.2-infected patients who received sotrovimab and nirmatrelvir for the prevention of severe COVID-19. The results showed that early administration of nirmatrelvir was associated with faster viral clearance compared to sotrovimab, which may contribute to reducing transmission and preventing viral resistance.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Letter
Immunology
Bruce Shinga Wembulua, Nadia Valin, Sidonie Lambert-Niclot, Estelle Nerozzi-Banfi, Thibault Chiarabini, Jean Luc Meynard, Karine Lacombe
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
(2023)
Article
Infectious Diseases
Antoine Bachelard, Valentina Isernia, Charlotte Charpentier, Aida Benalycherif, Marion Mora, Cecile Donadille, Claudine Duvivier, Karine Lacombe, Mayssam El Mouhebb, Bruno Spire, Roland Landman, Diane Descamps, Gilles Peytavin, Lambert Assoumou, Jade Ghosn, FAST sty grp
Summary: Initiating same-day ART for newly HIV-diagnosed individuals reduces transmission risk and improves treatment adherence. The BIC/FTC/TAF regimen has been shown to be safe, effective, and well accepted for same-day initiation.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Gastroenterology & Hepatology
Charles Beguelin, Andrew Atkinson, Anders Boyd, Karolin Falconer, Nikolai Kirkby, Franziska Suter-Riniker, Huldrych F. Guenthard, Juergen K. Rockstroh, Amanda Mocroft, Andri Rauch, Lars Peters, Gilles Wandeler
Summary: A study found a high prevalence of hepatitis delta virus (HDV) infection among persons living with HIV (PLWH) in Europe, which is the most severe form of viral hepatitis. This study analyzed data from a large HIV cohort collaboration to characterize the epidemiological trends of HDV in Europe and its impact on clinical outcomes.
LIVER INTERNATIONAL
(2023)
Article
Economics
Qinglu Cheng, Evan B. Cunningham, Sophy Shih, Janaki Amin, Julie Bruneau, Adelina A. Artenie, Jeff Powis, Alain H. Litwin, Curtis Cooper, Olav Dalgard, Margaret Hellard, Philip Bruggmann, Philippa Marks, Karine Lacombe, Catherine Stedman, Phillip Read, Behzad Hajarizadeh, Adrian J. Dunlop, Brian Conway, Jordan J. Feld, Gregory J. Dore, Jason Grebely
Summary: This study aimed to assess the change in patient-reported outcomes (PROs) during and after hepatitis C virus (HCV) direct-acting antiviral (DAA) treatment among people who inject drugs (PWID). The study found no significant improvement in health-related quality of life, social functioning, psychological distress, and housing, but there was a significant increase in employment. These results highlight the need for comprehensive models of HCV care for PWID to improve their quality of life.
Article
Medicine, General & Internal
Fabrice Cognasse, Hind Hamzeh-Cognasse, Mickael Rosa, Delphine Corseaux, Brigitte Bonneaudeau, Chloe Pierre, Julie Huet, Charles Antoine Arthaud, Marie Ange Eyraud, Amelie Prier, Anne Claire Duchez, Theo Ebermeyer, Marco Heestermans, Estelle Audoux-Caire, Quentin Philippot, Tom Le Voyer, Olivier Hequet, Anne-Marie Fillet, Patricia Chavarin, Dominique Legrand, Pascale Richard, France Pirenne, Pierre Gallian, Jean Laurent Casanova, Sophie Susen, Pascal Morel, Karine Lacombe, Paul Bastard, Pierre Tiberghien
Summary: COVID-19 convalescent plasma (CCP) contains neutralising antibodies that may be useful as passive immunotherapy. CCP showed increased levels of IL-6 and TNF-alpha and lower levels of IL-10 compared to control plasma. Auto-Antibodies against type I IFNs in CCP were not associated with reported adverse events. Further studies are needed to define the clinical relevance of these findings.
Article
Medicine, General & Internal
Daniela K. van Santen, Rachel Sacks-Davis, Ashleigh Stewart, Anders Boyd, Jim Young, Marc van der Valk, Colette Smit, Andri Rauch, Dominique L. Braun, Inmaculada Jarrin, Juan Berenguer, Jeffrey V. Lazarus, Karine Lacombe, Maria-Bernarda Requena, Linda Wittkop, Olivier Leleux, Dominique Salmon, Fabrice Bonnet, Gail Matthews, Joseph S. Doyle, Tim Spelman, Marina B. Klein, Maria Prins, Jason Asselin, Mark A. Stoove, Margaret Hellard
Summary: We assessed the impact of broad direct-acting antiviral (DAA) access on hepatitis C virus (HCV) incidence among people living with HIV (PLHIV) and found that it can significantly reduce HCV incidence, indicating a treatment as prevention effect.
Article
Gastroenterology & Hepatology
Oumarou Nabi, Nathanael Lapidus, Jerome Boursier, Victor de Ledinghen, Jean-Michel Petit, Sofiane Kab, Adeline Renuy, Marie Zins, Karine Lacombe, Lawrence Serfaty
Summary: This study compared the characteristics and mortality between lean and nonlean NAFLD patients by observing participants nationwide. The results showed that despite better metabolic profiles, lean individuals had higher levels of liver fibrosis, faster progression of liver disease, and increased rates of chronic kidney disease and overall mortality.
Article
Medicine, Research & Experimental
Kris Hage, Anders Boyd, Udi Davidovich, Paul Zantkuijl, Elske Hoornenborg, Amy Matser, Ellen Generaal, Janke Schinkel, Eve Todesco, Marc van der Valk, Hayette Rougier, Karine Lacombe, Maria Prins
Summary: The ICECREAM study aims to decrease the risk of HCV reinfection in MSM with previous HCV infection through online interventions and self-sampling tests, ultimately contributing to HCV micro-elimination.
Article
Gastroenterology & Hepatology
Fabienne Marcellin, Abbas Mourad, Maud Lemoine, Charles Kouanfack, Moussa Seydi, Patrizia Carrieri, Alain Attia, Camelia Protopopescu, Karine Lacombe, Sylvie Boyer
Summary: This study in Central and West Africa found that patients with chronic hepatitis C who received a 12-week sofosbuvir-based direct-acting antiviral regimen showed significant improvements in health-related quality of life, fatigue, and self-reported symptoms 24 weeks after treatment. These findings provide important insights for the treatment of hepatitis C in low-to-middle-income countries.
Article
Gastroenterology & Hepatology
Fabienne Marcellin, Sylvie Bregigeon-Ronot, Clemence Ramier, Camelia Protopopescu, Camille Gilbert, Vincent Di Beo, Claudine Duvivier, Morgane Bureau-Stoltmann, Eric Rosenthal, Linda Wittkop, Dominique Salmon-Ceron, Patrizia Carrieri, Philippe Sogni, Tangui Barre
Summary: This study aimed to investigate the prevalence of moderate-to-severe depression in people living with HIV and HCV after successful HCV treatment, and identify associated socio-behavioral factors. Through descriptive and logistic regression analyses of data from 398 participants, it was found that 23.9% of HCV-cured individuals had moderate-to-severe depression. Female sex, unhealthy alcohol use, sedentary lifestyle, and unhealthy eating behaviors were associated with increased odds of moderate-to-severe depression.
Article
Critical Care Medicine
Marius Troseid, Jose R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzic, Fulvia Mazzaferri, Jesus Rodriguez Bano, Joe Eustace, Maya Hites, Michael Joannidis, Jose-Artur Paiva, Jean Reuter, Isabel Puentmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Borresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Moller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Balde, Lucie de Gastines, Marta del Alamo, Burc Aydin, Fridtjof Lund-Johansen, Mary-Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Rottingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola
Summary: The study conducted a placebo-controlled trial of baricitinib in severe/critical COVID cases. The results showed that baricitinib did not reduce mortality within 60 days, and there may be safety risks in vaccinated participants, which require further investigation.
Article
Medicine, General & Internal
Olivier Hermine, Xavier Mariette, Raphael Porcher, Felix Djossou, Yann Nguyen, Jean-Benoit Arlet, Laurent Savale, Jean Luc Diehl, Sophie Georgin-Lavialle, Jacques Cadranel, Gilles Pialoux, Karine Lacombe, Arsene Mekinian, Helene Gros, Xavier Lescure, Jade Ghosn, Elisabeth Coupez, Kevin Grapin, Christophe Rapp, Marc Michel, Anne Lise Lecapitaine, Jean Marie Michot, Nathalie Costedoat-Chalumeau, Liem Binh Luong Nguyen, Luca Semerano, Francois Raffi, Claire Aguillar, Claire Rouzaud, Jacques Eric Gottenberg, Yves Hansmann, Boris Bienvenu, Jonathan London, Franklin Samou Fantchou, Felix Ackermann, Antoine Gros, Alexandre Morel, Nicolas Gambier, Damien Sene, Bruno Megarbane, Elie Azoulay, Serge Bureau, Maxime Dougados, Joseph Emmerich, Muriel Fartoukh, Bertrand Guidet, Marc Humbert, Mathieu Mahevas, Frederic Pene, Frederic Schlemmer, Valerie Pourcher-Martinez, Annick Tibi, Gabriel Baron, Elodie Perrodeau, Stephanie Baron, Gabriel Steg, Yazdan Yazdapanah, Tabassome Simon, Matthieu Resche-Rigon, Pierre-Louis Tharaux, Philippe Ravaud
Summary: The combination of dexamethasone and tocilizumab did not improve the need for mechanical ventilation and mortality in patients with moderate-to-severe COVID-19 pneumonia. The safety of both treatments was similar.
